Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Adult T-cell Leukemia-Lymphoma Clinical Trial

Official title:
A Phase II Trial of Belinostat as Consolidation Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Status Recruiting

Clinical Trial Summary

The investigators propose to use Belinostat in combination with AZT as consolidation therapy for the treatment of ATLL.

n/a

See also
Status	Clinical Trial	Phase
Completed	`NCT01724177` - A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma	Phase 2
Completed	`NCT01626664` - KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	Phase 2
Completed	`NCT00920790` - Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma	Phase 2
Completed	`NCT01173887` - Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15	Phase 2
Completed	`NCT01169298` - A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma	Phase 1